Last reviewed · How we verify
Nourianz (ISTRADEFYLLINE)
Nourianz (generic name: ISTRADEFYLLINE) is a CYP3A4 Substrates Small molecule drug developed by Kyowa Kirin. It is currently FDA-approved (first approved 2019) for Parkinson's disease.
Nourianz works by blocking the adenosine receptor A2a, which helps to increase dopamine levels in the brain.
Nourianz is a small molecule medication, specifically a pill containing istradefylline, which is being studied for various conditions including Parkinson Disease, Tremor, ALS, Spinal Cord Injuries, and Myelopathy. It is being investigated in clinical trials, such as NCT05885360, to assess its effects on these conditions.
At a glance
| Generic name | ISTRADEFYLLINE |
|---|---|
| Sponsor | Kyowa Kirin |
| Drug class | CYP3A4 Substrates |
| Target | Adenosine receptor A2a |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2019 |
Mechanism of action
The precise mechanism by which istradefylline exerts its therapeutic effect in Parkinson disease is unknown. In in vitro studies and in in vivo animal studies, istradefylline was demonstrated to be an adenosine A2A receptor antagonist.
Approved indications
- Parkinson's disease
Common side effects
- Dyskinesia
- Dizziness
- Constipation
- Nausea
- Hallucination
- Insomnia
- Diarrhea
- Decreased appetite
- Blood alkaline phosphatase increased
- Blood glucose increased
- Blood urea increased
- Upper Respiratory Tract Inflammation
Drug interactions
- P-glycoprotein Substrates
Key clinical trials
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1,PHASE2)
- Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury (PHASE1,PHASE2)
- Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
- Istradefylline for Parkinson Disease With Cognitive Impairment (PHASE2)
- Istradefylline Effect Protocol on Parkinson's Disease Tremor (PHASE4)
- An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001 (PHASE3)
- 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa (PHASE2)
- A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nourianz CI brief — competitive landscape report
- Nourianz updates RSS · CI watch RSS
- Kyowa Kirin portfolio CI
Frequently asked questions about Nourianz
What is Nourianz?
How does Nourianz work?
What is Nourianz used for?
Who makes Nourianz?
What is the generic name of Nourianz?
What drug class is Nourianz in?
When was Nourianz approved?
What development phase is Nourianz in?
What are the side effects of Nourianz?
What does Nourianz target?
Related
- Drug class: All CYP3A4 Substrates drugs
- Target: All drugs targeting Adenosine receptor A2a
- Manufacturer: Kyowa Kirin — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Parkinson's disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing